A Study of Single Dose of ABT-333 in Healthy Male Adults | NCT00919490 | Trialant

A Study of Single Dose of ABT-333 in Healthy Male Adults | NCT00919490 | Trialant

Arms/Interventions Module

Arm Groups

Label	Type	Description	Intervention Names
Group 1	Experimental	Single dose of 400 mg	Drug: ABT-333
Group 2	Experimental	Single dose of 800 mg after safety evolution of Group I	Drug: ABT-333
Group 3	Experimental	Single dose of 1200 mg after safety evolution of Group 2	Drug: ABT-333
Group 4	Experimental	Single dose of 1600 mg after safety evolution of Group 3	Drug: ABT-333
Group 5	Placebo Comparator	Single dose of placebo	Drug: Placebo

Outcomes Module

Primary Outcomes

Measure	Description	Time Frame
To assess single dose safety and tolerability of an ABT-333 tablet formulation relative to placebo by the evaluation of vital signs, ECGs, physical exams, clinical lab testing and adverse event monitoring		Daily assessment for 5 days then day 30 or more frequently as needed
To evaluate single dose pharmacokinetics of an ABT-333 tablet formulation		Day 1-3

Contacts/Locations Module